The Lancet Gastroenterology & Hepatology
@LancetGastroHep
Followers
24,214
Following
457
Media
2,785
Statuses
9,072
The Lancet Gastroenterology & Hepatology is the world-leading #gastroenterology and #hepatology research journal. IF=35.7.
Joined February 2016
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Drake
• 1944526 Tweets
Kendrick
• 1763353 Tweets
Lando
• 468609 Tweets
LISA TEAM REDBULL
• 446551 Tweets
#GranHermano
• 240064 Tweets
GW最終日
• 205483 Tweets
Furia
• 184850 Tweets
Menotti
• 150545 Tweets
Stars
• 141326 Tweets
MARTIN AL 9009
• 126634 Tweets
McLaren
• 102404 Tweets
Drizzy
• 100470 Tweets
Mauro
• 97710 Tweets
連休最終日
• 68431 Tweets
Bahia
• 66528 Tweets
Panamá
• 65934 Tweets
Mulino
• 55595 Tweets
FEDERICO
• 42215 Tweets
ゴールデンウィーク最終日
• 41439 Tweets
Juliana
• 35503 Tweets
#この漫画知っている人で100いいね
• 31650 Tweets
Tom Brady
• 23234 Tweets
Whitney
• 21488 Tweets
TERROR COM A ANA
• 19657 Tweets
Lombana
• 16839 Tweets
Larson
• 14401 Tweets
Del Moro
• 13070 Tweets
ゴムの日
• 11215 Tweets
#NASCAR
• 10240 Tweets
Pinned Tweet
As the world-leading gastroenterology and hepatology research journal, we publish the best science in the field globally. While a partial measurement of our reputation, we are delighted to share our Impact Factor of 35·7.
#GITwitter
#LiverTwitter
6
3
51
Ambitious targets by
@WHO
have been established to eliminate
#viralhepatitis
by 2030. New Commission provides scorecard of national progress to ascertain progress of high-burden countries towards these targets -
#nohep
5
139
754
#Free
for
#UEGWeek
- the microbiota–gut–brain axis in
#obesity
-
#microbiome
#microbiota
@jfcryan
@TedDinan
7
203
357
Viral
#hepatitis
is a major public health threat and a leading cause of death worldwide, killing 1·34 million people every year, similar numbers to deaths from HIV/AIDS, tuberculosis, or malaria—new Commission -
#nohep
5
124
213
New Review online — NASH drug treatment development: challenges and lessons, by Tilg, Byrne and Targher
A wide range of mechanisms are being studied; ideal
#NASH
candidates should be safe and hepatoprotective+cardioprotective
#MASLD
#MASH
#LiverTwitter
0
89
230
New
@TheLancet
Series on functional gastrointestinal disorders (disorders of gut-brain interaction) -
#UEGWeek
#gitwitter
#FGID
#DGBI
#IBS
#dyspepsia
4
79
195
New Review - Targher et al - Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease
#NAFLD
#MAFLD
#fattyliver
#livertwitter
0
53
182
New Review - Targher et al - Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach
#livertwitter
#NAFLD
#MAFLD
#fattyliver
0
82
181
New Review - Nuzzo et al - Prevention and treatment of nutritional complications after bariatric surgery
#gitwitter
@AlexandreNuzzo
@franciscajoly
#bariatricsurgery
#obesity
3
87
179
New Commission sets out priorities at national, regional, and global levels to accelerate progress towards elimination of
#viralhepatitis
by 2030 -
#nohep
1
32
143
Review: The microbiota–gut–brain axis in
#obesity
- -
#free
for
#WorldObesityDay
#microbiome
#microbiota
3
91
146
New research - Reynolds et al - Trimodality therapy vs perioperative chemotherapy for locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS phase 3 trial
#OncTwitter
#GITwitter
#EsoCSM
2
76
146
New research - Liu et al - Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial
#GITwitter
#OncTwitter
@OncoAlert
5
85
142
New Correspondence: Prolonged presence of
#SARSCoV2
viral RNA in faecal samples -
#gitwitter
#COVID19
3
110
139
New online - Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines
@IHPBA
@gbonneysurg
@eahpba
@_ilts_
#livertwitter
#APHPBA_2021
2
83
132
New research - Loomba et al - Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
#NASH
#NAFLD
#cirrhosis
#gitwitter
#livertwitter
#medtwitter
@DrLoomba
5
52
128
New research - Haifer et al - Lyophilised oral faecal microbiota transplantation for
#ulcerativecolitis
(LOTUS): a randomised, double-blind, placebo-controlled trial
#GITwitter
#IBD
#microbiome
#microbiota
#FMT
@rupertleong
2
44
123
New Review -
@MonicaTincopa
&
@drloomba
- Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
#NASH
#NAFLD
#fattyliver
#livertwitter
4
48
120
The
#mesentery
as an organ in its own right: its structure, function, and role in
#gastrointestinal
disease
#free
6
135
117
Neoadjuvant
#immunotherapy
for locally advanced dMMR/MSI-H
#colorectalcancer
resulted in pathological complete response in a high proportion of patients, according to new research. Read more here:
#crcsm
#GITwitter
0
47
112
A selection of highlights from
@LancetGastroHep
over the past 12 months - a mix of our most read, most discussed, and Editors' favourites 👉👉👉
#GITwitter
#LiverTwitter
3
33
114
Although effective treatments for
#hepC
exist, many individuals cannot access these drugs due to restrictions on reimbursements. Here’s a recent overview of such restrictions in Europe -
#nohep
#worldhepatitisday
5
54
102
This week's issue of
@TheLancet
features a new Seminar on
#liver
#cirrhosis
from Pere Ginès and colleagues -
#LiverTwitter
0
42
107
New Review - Quality standards for the management of non-alcoholic fatty liver disease (
#NAFLD
): consensus recommendations from the
@BASLedu
&
@BritSocGastro
NAFLD Special Interest Group
#fattyliver
#livertwitter
3
46
109
A thread of our
#COVID19
#gastroenterology
&
#hepatology
related content
1. Comment - Yeo et al - Enteric involvement of coronaviruses: is faecal–oral transmission of
#SARSCoV2
possible? (Feb 19, 2020)
#gitwitter
#livertwitter
3
61
101
New research - Siriwardena et al - A procalcitonin-based algorithm to guide antibiotic use in patients with acute
#pancreatitis
(PROCAP): a single-centre, patient-blinded, randomised controlled trial
#acutepancreatitis
#GITwitter
#AMR
@MFT_MRI
@MFTnhs
1
46
101
New Review - The relationship between gastrointestinal cancers and the microbiota
#gitwitter
#microbiota
#gastrointestinal
#cancer
@fredhutch
0
46
99
Comment on new Commission: Civil society’s critical role in the elimination of
#viralhepatitis
-
@Hep_Alliance
@RaqPeck
#nohep
0
20
89
Comment on new Commission: Elimination of
#viralhepatitis
by 2030: ambitious, but achievable -
#nohep
0
17
87
New Review - Tranah et al - Diagnosis and management of ectopic varices in portal hypertension
#LiverTwitter
@ThomasTranah
@DavidPatch1
@dtrip2015
@DebbieShawcros1
@TheBileDoc
@SarahHughesHep
0
31
93
Out now - results from the
@PROFILECrohn
trial, a biomarker-stratified comparison of top-down vs accelerated step-up treatment strategies for patients with newly diagnosed Crohn’s disease
#GITwitter
#IBD
#ECCO24
#ECCO2024
3
41
94
NEW Review online, exploring epidemiological to mechanistic evidence on the health effects of ultra-processed foods
#UPF
#GITwitter
@BenoitChassaing
@BernardSrour
@m_dch
@BonazziErica
@melissa_kordahi
1
61
92
New research - Aggressive fluid hydration plus NSAIDs versus NSAIDs alone for post-ERCP pancreatitis - the FLUYT trial
#gitwitter
#ERCP
#pancreatitis
@pancreatitis_nl
@joostphdrenth
@MarcBesselink
@rcverdonk
@PaulFockens
@christasw
4
44
92
New online
@TheLancet
- Amitriptyline at Low-Dose and Titrated for
#IBS
as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial
Catch the
#UEGWeek
presentation this pm by
@alex_ford12399
0
46
85
Check out a review on management of the multiple symptoms of
#irritablebowelsyndrome
-
#free
for
#UEGWeek
#IBS
#FGID
3
43
82
New Review - Parigi et al - Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting
#GITwitter
#IBD
@silvio_silvio75
@PeyrinBiroulet
@ibddocmaria
@vipuljairath
@IBDMD
@IOIBD1
2
31
79
Our latest issue is now live at . Includes content on
#alcohol
,
#IBD
,
#Hpylori
,
#HCV
,
#training
,
#livertransplantation
+ more!
#livertwitter
#gitwitter
#medtwitter
#transplanttwitter
1
19
80
Hartmann’s procedure versus sigmoidectomy with primary anastomosis for perforated
#diverticulitis
with purulent or faecal peritonitis (LADIES): a randomised trial -
#colorectalresearch
#colorectalsurgery
#SoMe4Surgery
1
52
77
New Review - Guillo et al - Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the IOIBD
@IOIBD1
@PeyrinBiroulet
@silvio_silvio75
#IBD
#GITwitter
0
37
74
5
74
75
Our June issue is now available at , including content on NASH cirrhosis, alcohol-related liver disease, irritable bowel syndrome, viral hepatitis, H pylori, eating disorders, inflammatory bowel disease + much more!
#gitwitter
#livertwitter
#medtwitter
0
27
75
New research -
@teoh_anthony
et al - Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre RCT
#GITwitter
#OncTwitter
#Endoscopy
2
41
75
1
50
73
New research - Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: retrospective long-term follow-up of the LIR!C trial -
#SoMe4Surgery
#IBD
#crohns
#crohnsdisease
#GITwitter
1
45
74
Today is
#InternationalNASHDay
- revisit our recent Editorial on redefining non-alcoholic fatty liver disease: what's in a name?
#NAFLD
#NASH
#fattyliver
#MASH
#MAFLD
#livertwitter
#free
2
34
73
New online -
#SARSCoV2
#vaccination
for patients with inflammatory bowel disease: a British Society of Gastroenterology
#IBD
section and
#IBD
Clinical Research Group position statement
@BritSocGastro
@NickPowellLab
@charlie_lees
@CrohnsColitisUK
2
49
73
Mental disorders frequently co-occur with irritable bowel syndrome.
Read more in this Viewpoint on the common mental disorders
#anxiety
and
#depression
in
#IBS
by
@hmstaudacher
@AntMikocka
&
@alex_ford12399
#WorldMentalHealthDay
#GITwitter
0
29
72
In our latest issue - Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines
#GITwitter
#LiverTwitter
#SoMe4Surgery
#TransplantTwitter
@IHPBA
@gbonneysurg
#crcsm
2
41
71
New research
@TheLancet
-
@babudayyeh
et al - Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a multicentre, randomised trial
#endoscopy
#gastroplasty
#obesity
#gitwitter
1
23
70
New Viewpoint - Shiha et al - Redefining fatty liver disease: an international patient perspective
#NAFLD
#MAFLD
#fattyliver
#livertwitter
@EuropeLiver
@Hep_Alliance
@asscatinforma
@ECPObesity
1
35
69
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: the prospective, multicentre PANTS cohort study -
#crohnsdisease
#crohns
#IBD
2
50
65
Rohit Loomba
@DrLoomba
kicks things off in the late breakers session at
#ILC2022
with data from a phase 2 RCT of semaglutide 2.4 mg once weekly for patients with
#NASH
-related
#cirrhosis
#livertwitter
2
13
66
New research - Lee et al - Trastuzumab plus FOLFOX for HER2-positive
#biliarytractcancer
refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14)
#gitwitter
#onctwitter
@oncoalert
0
27
66
9 in 10 cases of liver disease have preventable causes.
Our new Editorial explores the latest sobering data from
@OHID
that reveal sharp rises in hospital admissions due to liver disease in England
#livertwitter
1
25
67
New research - Targher et al - Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis
#livertwitter
#fattyliver
#CVD
#NAFLD
1
29
65
New Research - Morris et al - Impact of the
#COVID19
pandemic on the detection and management of
#colorectalcancer
in England: a population-based study
#crcsm
@EJAMorris
@Oxford_NDPH
@UniofOxford
@CR_UK
@NHSDigital
3
34
63
New
@TheLancet
- Verrastro et al - Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial
#NASH
#NAFLD
#fattyliver
#livertwitter
2
36
63
New Viewpoint - Geldof et al - Classifying perianal fistulising Crohn’s disease: an expert consensus to guide decision-making in daily practice and clinical trials
#Crohns
#fistula
#IBD
#GITwitter
@GeldofJeroen
@Nusiqbal
@philtozer1
@DrAilsaHart
1
26
63
Bruce Sands presents results from the head-to-head SEAVUE randomised trial of ustekinumab vs adalimumab for induction and maintenance in moderate-to-severe
#Crohns
disease
#DDW2021
#gitwitter
#IBD
1
23
63
New Review - Shribman et al - Investigation and management of Wilson's disease: a practical guide from the British Association for the Study of the Liver
#wilsonsdisease
#LiverTwitter
@tom_marjot
@BASLedu
@BritSocGastro
@theABN_Info
0
23
62
New Comment - Enteric involvement of coronaviruses: is faecal–oral transmission of
#SARSCoV2
possible?
#COVID19
#coronavirus
1
51
55
New research - Louis et al - Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial
#IBD
#GITwitter
#medtwitter
1
19
62
New review - Massironi et al - Inflammation and malnutrition in inflammatory bowel disease
@saramassironi
@PeyrinBiroulet
@silvio_silvio75
#gitwitter
#IBD
#malnutrition
#inflammation
3
20
59
New research - Wang et al - Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: a population-based systematic analysis of GLOBOCAN
#GITwitter
#OncTwitter
@IARCWHO
8
31
59
New research - Huang et al - Type 2 diabetes, hepatic decompensation & hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis
#LiverTwitter
#Diabetes
#NAFLD
#MASLD
6
30
59
Today we publish reviews from experts in the Middle East + North Africa and from Latin America on redefining non-alcoholic
#fattyliver
disease (
#NAFLD
). NAFLD prevalence is higher in these regions than elsewhere in the world.
1
21
58
New Research - Nguyen et al - Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden -
#GITwitter
#IBD
#ulcerativecolitis
#crohns
#crohnsdisease
1
26
55
New research - Danese et al - Treat to target versus standard of care for patients with Crohn’s disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial
#ulcerativecolitis
#IBD
#T2T
#GITwitter
@silvio_silvio75
3
20
55
On
#WorldObesityDay
we highlight recent calls to rename and redefine
#NAFLD
- the most prevalent chronic liver disease, associated with
#obesity
, as metabolic-associated fatty liver disease (
#MAFLD
)
An international patient
perspective -
#fattyliver
1
23
55
New research - Loras et al - Self-expandable metal stents versus endoscopic balloon dilation for the treatment of strictures in Crohn’s disease (ProtDilat study): an open-label, multicentre, randomised trial
#GITwitter
#Crohns
#IBD
@geteccu
#endoscopy
5
25
55
As the world-leading gastroenterology & hepatology research journal, we publish the best science in our fields. While a partial measurement of our reputation, we are delighted to share our Impact Factor of 45·042.
4
3
56
Radiological intervention (TIPS or BRTO) as secondary prophylaxis for gastric variceal haemorrhage reduced rebleeding but did not improve survival vs serial endoscopic injection sclerotherapy in the CRISP GV randomised trial
#TLM2023
#TLM23
#LiverTwitter
3
15
56
New
@TheLancet
- Qin et al - Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
#LiverTwitter
#OncTwitter
#LiverCancer
#HCC
0
19
55
New research - Sebastian et al - Assessment, endoscopy, and treatment in patients with acute severe
#ulcerativecolitis
during the
#COVID19
pandemic: the PROTECT-ASUC study
#IBD
#ASUC
#PROTECTASUC
@ibdseb
@DrNickKennedy
@DrChrisLamb
@CrohnsColitisUK
1
28
55
Our latest issue is out now at !
Content includes non-celiac gluten sensitivity, EUS-guided gastroenterostomy, treatments for Crohn's & faecal incontinence, NAFLD & cancer risk, & managing cirrhosis is limited-resource settings
#GITwitter
#LiverTwitter
2
19
55
New research - Ovadia et al - Ursodeoxycholic acid in intrahepatic
#cholestasis
of
#pregnancy
: a systematic review and individual participant data meta-analysis
@CarolineOvadia
@jennasaj
@CathWilliamson5
#ICP
#livertwitter
@NIHRresearch
@KingsCollegeLon
2
17
54
New Review -
@tom_marjot
et al - Sleep and liver disease: a bidirectional relationship
#sleep
#liver
#livertwitter
@Drfattyliver
2
22
55
Our latest issue is now live at , with new content about
#NAFLD
,
#CVD
,
#endoscopy
,
#livertransplantation
,
#colorectalcancer
,
#GIBleeding
,
#cholangiocarcinoma
+ more!
#GITwitter
#LiverTwitter
#MedTwitter
0
15
54
New Comment - Israelsen et al - MetALD: new opportunities to understand the role of alcohol in steatotic liver disease
#LiverTwitter
#MetALD
@IsraelsenMads
@AleksanderKrag
@MajaThiele
1
29
55
New research -
@IsraelsenMads
et al - Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial
#livertwitter
#fibrosis
#alcohol
@AleksanderKrag
@MajaThiele
1
23
54
In our latest issue - Treatment of
#pouchitis
,
#Crohn
's disease,
#cuffitis
, and other inflammatory disorders of the
#pouch
: consensus guidelines from the International Ileal Pouch Consortium
#GITwitter
1
19
54
We are indexed in the Web of Science Core Collection (ESCI), MEDLINE/PubMed, Embase, and Scopus—consider us for publication. Visit for more information.
0
14
50
New Review - Bo Shen et al - Treatment of pouchitis, Crohn’s disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium
#GITwitter
#pouch
#ilealpouch
1
23
54
New research - five trials of etrolizumab for moderately to severely active ulcerative colitis
HIBISCUS I & II -
GARDENIA -
HICKORY -
LAUREL -
#GItwitter
#IBD
#ulcerativecolitis
1
21
53
New
@TheLancet
- 2 days versus 5 days of postoperative antibiotics for complex appendicitis: a pragmatic, open-label, multicentre, non-inferiority randomised trial
#gitwitter
#SoMe4Surgery
3
14
54
New Online: Use of anti-TNFα therapy for
#inflammatoryboweldisease
,
#rheumatoidarthritis
, or
#psoriasis
is not associated with development of recurrent or new primary
#cancer
in patients with previous cancer diagnosis -
@AkbarWaljee
@ibddoctor
2
34
52
New
@TheLancet
- Sands et al - Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease (SEAVUE trial)
#IBD
#GITwitter
#Crohnsdisease
0
24
52
New Review - Singh et al - Management of inflammatory bowel diseases in older adults
#IBD
#GITwitter
@BolandBrigid
@DrTineJess
@AlisonMooreMD
@UCSD_GI
@UCSDHealth
@UCSDGeriatrics
@PREDICTIBD
0
15
53
New research - Kobayashi et al - Discontinuation of infliximab in patients with
#ulcerativecolitis
in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial
#IBD
#gitwitter
@TakuKobayashiM1
2
21
52
New research - Singh et al - Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis
#IBD
#Crohnsdisease
#GITwitter
3
18
51
Paolo Angeli notes that one of the major
#hepatology
highlights of 2022 is the
@EASLnews
-
@TheLancet
Commission on liver disease in Europe. Read the Commission in full here:
#uegweek
#livertwitter
#uegweek22
0
15
51
New
@TheLancet
- Cytosponge-trefoil factor 3 versus usual care to identify
#Barrett
's
#oesophagus
in a primary care setting (the
#BEST3
trial) -
#Barretts
#esophagus
#oesophagealcancer
#esocsm
#esophagealcancer
@RFitzgerald_lab
0
24
50
Today is World Digestive Health Day, with the theme of obesity, an ongoing pandemic.
Read our recent Editorial on this topic -
#WDHD2021
#obesityawareness
#obesity
#Obesityanongoingpandemic
@WorldGastroOrg
#free
#gitwitter
#livertwitter
1
25
50
New Comment - Maurice et al - Green
#endoscopy
: a call for sustainability in the midst of
#COVID19
#GITwitter
@GreenEndoscopy
@IBDdoc
@IBDseb
@williamstablef1
@drkeithsiau
@dremmaw
@jamesbmaurice
#endoscopy
1
23
51
New Equity in Digestive Health Comment - Manmeet Matharoo, Amrita Sethi & Aline Charabaty - Towards meaningful change: the future of gastroenterology belongs to women, diversity, equity, and inclusion
#gitwitter
#WomeninGI
#diversityinGI
5
18
50